Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences
Open Access
- 31 May 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 26 (16), 3116-3129
- https://doi.org/10.1093/hmg/ddx196
Abstract
In-frame premature termination codons (PTCs) account for ∼11% of all disease-associated mutations. PTC suppression therapy utilizes small molecules that suppress translation termination at a PTC to restore synthesis of a full-length protein. PTC suppression is mediated by the base pairing of a near-cognate aminoacyl-tRNA with a PTC and subsequently, the amino acid becomes incorporated into the nascent polypeptide at the site of the PTC. However, little is known about the identity of the amino acid(s) inserted at a PTC during this process in mammalian cells, or how the surrounding sequence context influences amino acid incorporation. Here, we determined the amino acids inserted at the cystic fibrosis transmembrane conductance regulator (CFTR) W1282X PTC (a UGA codon) in the context of its three upstream and downstream CFTR codons during G418-mediated suppression. We found that leucine, cysteine and tryptophan are inserted during W1282X suppression. Interestingly, these amino acids (and their proportions) are significantly different from those recently identified following G418-mediated suppression of the CFTR G542X UGA mutation. These results demonstrate for the first time that local mRNA sequence context plays a key role in near-cognate aminoacyl-tRNA selection during PTC suppression. We also found that some variant CFTR proteins generated by PTC suppression exhibit reduced maturation and activity, indicating the complexity of nonsense suppression therapy. However, both a CFTR corrector and potentiator enhanced activity of protein variants generated by G418-mediated suppression. These results suggest that PTC suppression in combination with CFTR modulators may be beneficial for the treatment of CF patients with PTCs.Keywords
Funding Information
- National Institutes of Health (R21 NS090928 (to D.M.B. and K.M.K.), R21 OD019922 (to K.M.K.), and P30 DK072482 (to S.M.R.))
- Cystic Fibrosis Foundation
- National Cancer Institute (P30 CA13148-38)
This publication has 47 references indexed in Scilit:
- Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved SequencesCell, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809Proceedings of the National Academy of Sciences of the United States of America, 2011
- Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54Journal of Molecular Medicine, 2011
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationNew England Journal of Medicine, 2010
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences of the United States of America, 2009
- Modulating the activity of the peptidyl transferase center of the ribosomeRNA, 2008
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse modelProceedings of the National Academy of Sciences of the United States of America, 2008
- Restoration of W1282X CFTR Activity by Enhanced ExpressionAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database SearchAnalytical Chemistry, 2002